Skip to product information
1 of 1

GeneBio Systems

VEGFA Polyclonal Antibody

VEGFA Polyclonal Antibody

SKU:E-AB-52121

Regular price €489,95 EUR
Regular price Sale price €489,95 EUR
Sale Sold out
Shipping calculated at checkout.

Size: 200μL

Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date: 12 months

Category ID_II: Primary Antibodies

Category ID_III: Polyclonal Antibodies

Abbreviation: VEGFA

Target Synonym: Folliculostellate cell-derived growth factor;Glioma-derived endothelial cell mitogen;MGC70609;MVCD1;Vascular endothelial growth factor A;vascular endothelial growth factor A121;vascular endothelial growth factor A165;vascular endothelial growth factor;Vascular permeability factor;VEGF A;Vegf;VEGF-A;VEGF120;Vegfa;VEGFA;VPF

Research Areas: Cancer;Cardiovascular;Metabolism;Developmental Biology;Signal Transduction

Conjugation: Unconjugated

Host: Rabbit

Species reactivity: Human;Mouse

Application: WB

Isotype: IgG

Clonality: Polyclonal

Clone NO.:

UNIProt ID: P15692

Accession:

Background: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Concentration: 1.3 mg/mL

Immunogen: Synthetic peptide of human VEGFA

Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4

Purification method: Antigen affinity purification

Dilution: WB 1:1000-1:5000

Calculated MW: 27 kDa

ObservedMW: Refer to figures

View full details